BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Etemadifar M, Sedaghat N, Nouri H, Lotfi N, Chitsaz A, Khorvash R, Zolfaghari H, Ghasemi Movaghar A, Pourabbas M, Salari M. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. Mult Scler Relat Disord 2021;57:103417. [PMID: 34875487 DOI: 10.1016/j.msard.2021.103417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Etemadifar M, Nouri H, Salari M, Sedaghat N. Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Hum Vaccin Immunother 2022;18:2033540. [PMID: 35239452 DOI: 10.1080/21645515.2022.2033540] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Etemadifar M, Abhari AP, Nouri H, Sigari AA, Piran Daliyeh SM, Maracy MR, Salari M, Maleki S, Sedaghat N. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. Hum Vaccin Immunother 2022;18:2041945. [PMID: 35201963 DOI: 10.1080/21645515.2022.2041945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cauchi M, Willis M, Andrews A, Backx M, Brownlee W, Ford HL, Gran B, Jolles S, Price S, Rashid W, Schmierer K, Tallantyre EC. Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Pract Neurol 2022:practneurol-2022-003370. [PMID: 35863879 DOI: 10.1136/practneurol-2022-003370] [Reference Citation Analysis]
4 Gombolay GY, Dutt M, Tyor W. Immune responses to SARS‐CoV ‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis. Ann Clin Transl Neurol. [DOI: 10.1002/acn3.51628] [Reference Citation Analysis]
5 Etemadifar M, Nouri H, Pitzalis M, Idda ML, Salari M, Baratian M, Mahdavi S, Abhari AP, Sedaghat N. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. J Neurol Neurosurg Psychiatry 2022:jnnp-2022-329123. [PMID: 35688629 DOI: 10.1136/jnnp-2022-329123] [Reference Citation Analysis]
6 Farid E, Herrera-uribe J, Stevenson NJ. The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine. Front Immunol 2022;13:817597. [DOI: 10.3389/fimmu.2022.817597] [Reference Citation Analysis]
7 Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Türkoğlu R, Baliç N, Kızılay T, Erol R, Akbayır E, Yılmaz V, Tüzün E. Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis. Mult Scler Relat Disord 2022;58:103524. [PMID: 35033838 DOI: 10.1016/j.msard.2022.103524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]